A Multi-Center Open-Label Phase 1/2 Study of BGB324 in Combination with Erlotinib in Patients with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (BGBC004)

June 22, 2018
https://clinicaltrials.gov/ct2/show/NCT02424617
Cancer - Lung
Principal Investigator: Igor I Rybkin, MD
lung cancer, lung, cancer, BGBC004
Accepting Participants